p53 (17-26) acetate
Based on 1 Customer Validation
p53 (17-26) acetate is a peptide derived from the P53 MDM2 binding domain, with a Kd of 50 nM for MDM2. p53 (17-26) acetate causes cell lysis by damaging cancer cells and nuclear membranes, and induces cancer cell necrosis. p53 (17-26) acetate exhibits antitumor activity and is applicable to research related to pancreatic cancer.
연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.
- 화학식: C60H90N12O17·xC2HF3O2
- 분자량:1251.43 (free base)
-
보관:
Sealed storage, away from moisture.
Powder -80°C, 2 years , -20°C, 1 year* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Biological Activity
제품 설명
In Vitro
p53 (17-26) acetate binds tightly to the N-terminal domain of MDM2 (Kd = 50 nM) and induces global conformational changes in the MDM2 domain[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
In Vivo
p53 (17-26) (1-20 mg; subcutaneous osmotic pump; 14 days) acetate dose-dependently inhibits the growth of established subcutaneous xenograft pancreatic cancer in nude mice[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Hsd:Athymic Nu/Nu (7-8 weeks old, 22-24 g, i.p. xenotransplantation of BMRPA1.Tuc3 pancreatic carcinoma cells)[2]
-
Dosage:2 mg/mouse
-
Administration:subcutaneous osmotic pump; constant rate 0.25 μL/hr; 14 days
-
Result:Prevented ascites or liver metastasis on day 21.
Contained no viable tumor cells in peritoneal lavage fluid, only macrophages and lymphocytes that did not grow in culture.
-
Animal Model:Hsd:Athymic Nu/Nu (7-8 weeks old, 22-24 g, s.c. xenotransplanted BMRPA1.Tuc3 pancreatic carcinoma cells grown to 40-260 mg before treatment)[2]
-
Dosage:20 mg/mouse; 10 mg/mouse; 1 mg/mouse
-
Administration:subcutaneous osmotic pump; 14 days
-
Result:Reduced average tumor size.
Inhibited post-treatment tumor growth.
Caused no weight loss or toxicity in treated mice.
Chemical Information
-
Appearance Solid
-
분자량 1251.43 (free base)
-
화학식 C60H90N12O17·xC2HF3O2
-
Sequence
Glu-Thr-Phe-Ser-Asp-Leu-Trp-Lys-Leu-Leu
-
Sequence Shortening
ETFSDLWKLL
-
선적
Room temperature in continental US; may vary elsewhere.
-
보관
Sealed storage, away from moisture
Powder -80°C 2 years -20°C 1 year * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Protocol
-
Protein Extraction
Protein extraction uses physical, chemical or biological methods, such as ultrasonic disruption, salting out, cell lysis, electrophoresis, etc., to destroy the cell membrane structure and to separate the proteins from different components according to their characteristics.
-
Subcutaneous Cell-Line-Derived Xenograft
Subcutaneous cell-line-derived xenograft (CDX) models are established by implanting cultured human cancer cell lines into immunodeficient mice, where the injected cells form localized tumors that can be monitored in vivo as a measure of tumorigenic potential, growth kinetics, and treatment response. These models are widely used in oncology research because they allow reproducible tumor formation and enable comparative assessment of tumor growth between different cell lines or genetic manipulations in a controlled in vivo microenvironment. Subcutaneous implantation of cancer cells in immunodeficient mice is a standard approach for evaluating tumor growth behavior and therapeutic response across multiple cancer types, including prostate, esophageal, pancreatic, and colon cancer models.
순도&문서
-
Data Sheet (272 KB)
-
SDS (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Handling Instructions (2659 KB)
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)